Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram?

Neurosciences

Volumn 16, Issue 1, 2011, Pages 42-45

  Khazaie, Habibolah ^a   Rahimi, Mehrali ^a   Tatari, Faeze ^a   Rezaei, Mansour ^a   Najafi, Farid ^a   Tahmasian, Masoud ^a  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERVIEW; MAJOR DEPRESSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; CITALOPRAM; DEPRESSION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79951893861     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Nau DP, Aikens JE, Pacholski AM. Effects of gender and depression on oral medication adherence in persons with type 2 diabetes mellitus. Gend Med 2007; 4: 205-213.
2. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebocontrolled trial. Diabetes Care 2000; 23: 618-623.
3. Sacco WP, Wells KJ, Friedman A, Matthew R, Perez S, Vaughan CA. Adherence, body mass index, and depression in adults with type 2 diabetes: the mediational role of diabetes symptoms and self-efficacy. Health Psychol 2007; 26: 693-700.
4. Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 2008; 79: 61-67.
5. Simon GE, Katon WJ, Lin EH, Rutter C, Manning WG, Von Korff M, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry 2007; 64: 65-72.
6. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 2001; 13: 31-41. Review.
7. Amsterdam JD, Shults J, Rutherford N, Schwartz S. Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus. Neuropsychobiology 2006; 54: 208-214.
8. Tollefson GD, Bosomworth JC, Heiligenstein JH, Potvin JH, Holman S. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995; 7: 89-104.
9. Keslsey J. Selective Serotonin Reuptake Inhibitors. In: Sadock BJ, Sadock VA. Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment. Philadelphia (PA): Lippincott Williams & Wilkins: 2001. p. 186-204.
10. Potter van Loon BJ, Radder JK, Frölich M, Krans HM, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord 1992; 16 Suppl 4: S55-S61.